Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.

被引：0
|
作者：
Reece, DE
Vesole, D
Flomenberg, N
Badros, A
Filicko, J
Herzig, R
Howard, DS
Johnson, V
Meisenberg, B
Rapoport, A
Xun, CQ
Phillips, GL
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Kentucky, Lexington, KY 40506 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [31] Transplant outcomes after topotecan-melphalan-cyclophosphamide (TMC) conditioning for autologous stem cell transplantation for multiple myeloma. comparison to melphalan 200 mg/M2 (MEL200).
    Donato, M
    Aleman, A
    Weber, D
    Wang, M
    Qazilbasch, M
    Davis, M
    Roden, L
    Mendoza, F
    Champlin, R
    Giralt, S
    BLOOD, 2005, 106 (11) : 344A - 344A
  • [32] Tolerability of high-dose melphalan 200 mg/m2 in patients with myeloma and leukemia over the age of 65 years: a single center study of 42 patients
    Powles, R
    Sirohi, B
    Singhal, S
    Kulkarni, S
    Patel, G
    Brennan, J
    Treleaven, J
    Stephens, M
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2003, 31 : S78 - S78
  • [33] Prospective, randomized comparison between double mransplantation (T) with melphalan (200 mg/m2) and triple T with intermediate dose melphalan (100 mg/m2) in patients with multiple myeloma (an interim analysis).
    Ludwig, Heinz
    Linkesch, Werner
    Kasparu, Hedwig
    Krieger, Otto
    Spicka, Ivan
    Gastl, Gunther
    Greil, Richard
    Drach, Johannes
    Thaler, Josef
    Kuhn, Ingrid
    Zojer, Niklas
    Hinke, Axel
    BLOOD, 2006, 108 (11) : 878A - 879A
  • [34] A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S293 - S294
  • [35] A Lower Dose Of Melphalan (140 mg/m2) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison M.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2013, 122 (21)
  • [36] Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/m2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial
    Abidi, Muneer H.
    Tageja, Nishant
    Lum, Lawrence G.
    Abrams, Judith
    Al-Kadhimi, Zaid
    Ayash, Lois
    Cronin, Simon
    Ventimiglia, Marie
    Deol, Abhinav
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    BLOOD, 2010, 116 (21) : 995 - 996
  • [37] High-dose therapy (HDT) with melphalan and autologous stem cell transplantation (ASCT) for patient older than 70 years with multiple myeloma - feasible therapy or significant risk of complications?
    Brockhoff, H.
    zum Bueschenfelde, Meyer C.
    Salwender, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 67 - 68
  • [38] EXCELLENT LONG-TERM OUTCOME OF AUTOLOGOUS TRANSPLANTATION WITH INTERMEDIATE-DOSE INTENSIVE MELPHALAN (100 MG/M2, MEL100) FOR MULTIPLE MYELOMA: A SINGLE CENTRE STUDY
    Fukushima, K.
    Sudo, T.
    Tamaki, T.
    HAEMATOLOGICA, 2015, 100 : 612 - 612
  • [39] High-dose therapy followed by autologous HSCT in patients with multiple myeloma. Results of a retrospective Multicenter analysis conducted by the polish myeloma group
    Knopinska-Posluszny, Wanda M.
    Hellmann, Andrzej
    Taszner, Michal
    Dmoszynska, Anna
    Jedrzejczak, Wiktor
    Holowiecki, Jerzy
    Walewski, Jan
    Warzocha, Krzysztof
    Skotnicki, Aleksander
    Lange, Andrzej
    Kuliczkowski, Kazimielrz
    Sulek, Kazimierz
    Komamicki, M.
    Robak, Tadcusz
    BLOOD, 2007, 110 (11) : 358B - 358B
  • [40] Long-term results (10 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
    Moreau, P
    Misbahi, R
    Milpied, N
    Morineau, N
    Mahé, A
    Vigier, M
    Rapp, MJ
    Bataille, R
    Harousseau, JL
    BLOOD, 2001, 98 (11) : 684A - 685A
12345